Age Trial
Trial question
What is the role of mammographic screening on breast cancer mortality in females aged 39-41 years?
Study design
Multi-center
Open label
RCT
Population
160921 female patients
Inclusion criteria: females aged 39-41 years
Key exclusion criteria: men, not traceable at NHSCR, deceased before entry, or emigrated before entry
Interventions
N=53884 intervention (annual mammography to age 48 years)
N=106956 control (usual medical care)
Primary outcome
Rate of breast-cancer death at a mean follow-up of 10.7 years
1.8
2.2
2.2 %
1.7 %
1.1 %
0.6 %
0.0 %
Intervention
Control
No significant difference ↔
No significant difference in the rate of breast-cancer death at a mean follow-up of 10.7 years (1.8% vs. 2.2%; RR 0.83, 95% CI 0.66 to 1.04)
Secondary outcomes
No significant difference in death from all causes (16.6% vs. 17.2%; RR 0.97, 95% CI 0.89 to 1.04)
No significant difference in the rate of breast-cancer death from 0-5 years (1% vs. 1.2%; RR 0.79, 95% CI 0.48 to 1.27)
No significant difference in the rate of breast-cancer death from 5-15 years (2.5% vs. 3%; RR 0.84, 95% CI 0.64 to 1.1)
Conclusion
In females aged 39-41 years, intervention was not superior to control with respect to the rate of breast-cancer death at a mean follow-up of 10.7 years.
Reference
Moss SM, Cuckle H, Evans A et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006 Dec 9;368(9552):2053-60.
Open reference URL